RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles

Amy Webb1,2, Audrey C. Papp1, Amanda Curtis1, Leslie C. Newman1, Maciej Pietrzak1,3, Michal Seweryn3, Samuel K. Handelman1, Grzegorz A. Rempala3, Daqing Wang4, Erica Graziosa4, Rachel F. Tyndale5, Caryn Lerman6, John R. Kelsoe7,8, Deborah C. Mash9 and Wolfgang Sadee1,10,11,12*

Abstract

Background: We used RNA sequencing to analyze transcript profiles of ten autopsy brain regions from ten subjects. RNA sequencing techniques were designed to detect both coding and non-coding RNA, splice isoform composition, and allelic expression. Brain regions were selected from five subjects with a documented history of smoking and five non-smokers. Paired-end RNA sequencing was performed on SOLiD instruments to a depth of >40 million reads, using linearly amplified, ribosomally depleted RNA. Sequencing libraries were prepared with both poly-dT and random hexamer primers to detect all RNA classes, including long non-coding (lncRNA), intronic and intergenic transcripts, and transcripts lacking poly-A tails, providing additional data not previously available. The study was designed to generate a database of the complete transcriptomes in brain region for gene network analyses and discovery of regulatory variants.

Results: Of 20,318 protein coding and 18,080 lncRNA genes annotated from GENCODE and Lncipedia, 12 thousand protein coding and 2 thousand lncRNA transcripts were detectable at a conservative threshold. Of the aligned reads, 52 % were exonic, 34 % intronic and 14 % intergenic. A majority of protein coding genes (65 %) was expressed in all regions, whereas ncRNAs displayed a more restricted distribution. Profiles of RNA isoforms varied across brain regions and subjects at multiple gene loci, with neurexin 3 (NRXN3) a prominent example. Allelic RNA ratios deviating from unity were identified in > 400 genes, detectable in both protein-coding and non-coding genes, indicating the presence of cis-acting regulatory variants. Mathematical modeling was used to identify RNAs stably expressed in all brain regions (serving as potential markers for normalizing expression levels), linked to basic cellular functions. An initial analysis of differential expression analysis between smokers and nonsmokers implicated a number of genes, several previously associated with nicotine exposure.

Conclusions: RNA sequencing identifies distinct and consistent differences in gene expression between brain regions, with non-coding RNA displaying greater diversity between brain regions than mRNAs. Numerous RNAs exhibit robust allele selective expression, proving a means for discovery of cis-acting regulatory factors with potential clinical relevance.

Keywords: RNA sequencing, Brain regions, Differential expression, Allelic expression imbalance, Isoform fraction, Non-coding RNA

* Correspondence: Wolfgang.Sadee@osumc.edu
1 Center for Pharmacogenomics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
10 Departments of Pharmacology, College of Medicine; Colleges of Pharmacy and Environmental Health Sciences, The Ohio State University, Columbus, OH, USA
Full list of author information is available at the end of the article

© 2015 Webb et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

The architecture and connectivity of brain regions critically influence CNS functions, including cognition, behavior, decision making and emotional control. Deregulation of dynamic CNS processes lead to psychiatric disorders, including depression, schizophrenia, and addiction. A mirror of the dynamic biological processes underlying brain functions, RNA transcript profiles have been measured in numerous studies, mostly with focus on protein-coding mRNAs, using targeted analysis or cDNA hybridization technology [1–3]. However, less than 2 % of the human genome accounts for protein-coding transcripts, while a large portion of the genome expresses non-coding RNAs, implicated in multiple biological roles regulating gene expression, guiding epigenetic processes, sensing cellular substrates, serving as catalysts or enzymes, and supporting structural functions [4]. Moreover, a majority of disease risk alleles implicated by genome-wide association studies (GWAS) reside outside protein coding exons, afecting transcription of all RNA types and RNA processing—areas still incompletely resolved [5, 6].

Next generation sequencing of RNA profiles (RNAseq) has opened the door for systematic exploration of the entire transcriptome, including genetic and epigenetic factors, and regulatory networks that often cannot be a reconstructed from protein-coding RNAs alone [2, 7, 8]. While this technology is rapidly maturing, different technology platforms and tissue preparation procedures have strong effects on results and interpretation [7, 9]. Recent studies have explored the transcriptome of the human brain, with increasing use of RNAseq, comparing brain autopsy regions from subjects with no previous diagnosis of a CNS disorder with regions from subjects with various diagnoses such as schizophrenia, alcohol dependence, and chronic nicotine exposure [8, 10–15]. More detailed analyses have been done with laser microdissection to minimize issues arising with RNAseq data obtained from heterogeneous regions [15]. Where use of heterogeneous regions cannot be avoided, computational deconvolution of co-expression gene networks can serve to dissect expression profiles for cellular subtypes [16]. Together, studies on CNS transcriptome profiles have revealed a wealth of candidate genes implicated in CNS functions and disorders.

In this study, we have measured RNAseq profiles in 10 brain regions from 10 human subjects, to generate a database for regional expression and inter-individual variability. Moreover, our study provides detailed data on RNA expression profiles, reflecting all types of RNA classes and RNA isoforms at each gene locus, supplementing existing studies involving human brain regions using hybridization arrays and large-scale genotyping, revealing multiple cis-acting quantitative expression traits (cis-eQTLs) and SNPs associated with CpG methylation patterns [1, 3, 13, 17, 18]. With microarrays using probes for multiple exons per gene, cis-eQTLs were found to be frequently associated with only some exons in a given gene, implicating a pervasive genetic influence on splicing [3], which is often region specific [19, 20]. However, microarray analysis is limited in detecting RNA transcript isoforms, whereas deep sequencing reveals the rich abundance of isoforms at each gene locus [7, 21].

RNAseq is typically performed with poly-dT to capture poly-adenylated RNA transcripts—these include most protein-coding mRNAs and numerous ncRNAs, but numerous RNAs do not carry a poly-A tail. To account for the emerging functions and interactions of all RNA classes, including non-coding RNAs, we have applied RNAseq in a process that captures all transcripts, regardless of polyadenylation status [7]. In this report, we focus on long RNAs (>200 bases), owing to the available RNAseq protocols that require a separate approach for measuring small RNAs, such as microRNAs—these will be reported in a subsequent study. Owing to the use of random hexamer primers in this study that captures non-polyadenylated RNAs as well, we were also interested in determining the relative abundances of the various RNA classes, protein-coding and non-coding, across brain regions.

Use of RNAseq enables us to measure transcript abundance and RNA isoforms, such as splice variants, different 3’ and 5’ UTRs, and edited RNAs [7, 21]. In addition, we have developed a quantitative approach to exploit RNAseq data for measuring allelic RNA expression ratios, a sensitive indicator of regulatory variants affecting gene expression and RNA processing [22]. To enable full analysis of allelic RNA expression, we have also applied whole-genome SNP chip analysis, as reported before in detecting cis-eQTLs [3, 6, 13], facilitating allele calling in RNA transcripts, detecting cases of RNA editing [22] and of mono-allelic expression, and alerting to the presence of copy number variants.

Of the ten subjects in this study, five were previous long-term smokers and 5 were non-smokers, all lacking other diagnoses of psychiatric disorders. While the number of subjects is small for detecting nicotine-related changes, we expected to develop leads for further study because nicotine exerts rather robust effects on cellular biology throughout the body [3, 23]. Our analyses were guided by previous studies on the influence of nicotine on brain transcriptomes, genetic effects on nicotine related genes [3, 23–25], and candidate genes associated with smoking from multiple studies [26]. By comparing RNA profiles in different human autopsy brain regions, we initiate here a comprehensive study of the brain transcriptome, interactive networks between RNAs, and
genetic factors regulating expression, with nicotine exposure serving as a perturbing environmental stimulus.

Methods
Postmortem human brain tissues
Brain tissue samples from five male subjects with a history of heavy cigarette smoking and five age-matched male drug-free controls were provided by the Miami Brain Endowment Bank™ (University of Miami, Miami, FL) following protocols approved by the research ethics board of the University of Miami Miller School of Medicine [27–32]. Brain biospecimens were banked from persons at autopsy. The authorization for retention of brain and tissues, medical records review, and informant interviews were approved by the University of Miami Institutional Review Board (Protocol No. 19920580). Ethical procedures including donor anonymity are assured. All brain tissue is procured, stored, and distributed according to applicable regulations and guidelines involving consent, protection of human subjects and donor anonymity. The genomics analyses on the de-identified autopsy brain tissues were exempt from IRB approval at OSU. Supplemental brain and blood toxicology and neuropathologic evaluations were done in every case. Subjects were selected from accidental or cardiac sudden deaths with negative urine screens for all common drugs, except nicotine, and there was no history of psychiatric or medical disorders or licit or illicit drug use prior to death. From each subject, ten brain regions were obtained to provide a diverse set of brain regions: frontopolar cortex (Brodmann Area 10; BA10), Wernicke’s area (BA22), anterior cingulate cortex (BA24), dorsolateral prefrontal cortex (BA46), insular cortex, hippocampus, amygdala, posterior putamen, cerebellum, and brainstem raphe nuclei.

RNA preparation
Frozen brain tissue was homogenized in Trizol (Invitrogen/Life Technologies, Carlsbad, CA), and then phase separated with chloroform. The RNA containing aqueous layer was diluted in binding buffer and applied to Qiagen (Venlo, Limburg, Netherlands) or Denville (South Plainfield, NJ) RNA isolation columns. The bound RNA was DNase treated and eluted according to kit procedures. RNA concentration was measured using Qubit (Invitrogen/Life Technologies, Carlsbad, CA), and integrity assessed by Bioanalyzer (Agilent, Santa Clara, CA). Samples with RIN numbers >6 were used for analysis.

cDNA synthesis
Fifty nanograms of total RNA was converted to cDNA and isothermally amplified using the NuGen Ovation RNA-Seq kit procedures (NuGen, San Carlos, CA). NuGEN’s proprietary SPIA technology is an elegant method for robust isothermal amplification of nucleic acids. Primer design strategies enable selective depletion of ribosomal RNA while amplifying all remaining coding and non-coding transcripts regardless of polyadenylation status. The resulting double stranded cDNA can be made into NGS libraries in a streamlined workflow bypassing any sequence enrichment procedure, leading to improved efficiency, throughput and data quality. Typically, 50 ng of input total RNA yielded 3–6 micrograms of double stranded cDNA. Ribosomal RNA was reduced to 3–5 % by the NuGen process. The yield of cDNA produced by isothermal amplification typically eliminates the need for additional PCR cycles, thus greatly reducing PCR duplicates in the final libraries.

Library preparation
The NuGen brain cDNA was sheared to approximately 150 bp fragments using the Covaris S (Woburn, MA). After shearing, fragments were recovered by centrifuging over an YM-30 spin filter (Amicon, Merck Millipore, Billerica, MA). Fragments greater than 100 bp were retained and eluted from the membrane, with ~ 90 % recovery. Bar-coded paired-end SOLiD sequencing libraries were prepared using either SOLiD (Applied Biosystems/Life Technologies, Carlsbad, CA) or NEB (New England Biolab, Ipswich, MA) DNA library preparation kits. The cDNA was end repaired, and then bar-coded SOLiD DNA sequencing adapters were ligated to 1 microgram of input cDNA according to kit instructions. Ligated library product was size selected using a Pippin gel electrophoresis system (Sage Biosciences, Beverly, MA). The prepared library was enriched for correctly adapted product using 5–8 cycles of PCR. Library PCR product was analyzed for appropriate size distribution with the Bioanalyzer, and quantitated using qPCR with the library adaptors on an Applied Biosystems 7500 Real-Time instrument. To confirm RNAseq measured expression, qRTPCR based expression was calculated as ΔΔCt with three invariable genes (AGO1, SPEN, SRSF11) averaged for baseline normalization.

Emulsion PCR, enrichment, slide preparation
To prepare libraries for sequencing on the SOLiD 4 or SOLiD 5500XL, the SOLiD EZ Beader System (Applied Biosystems/Life Technologies, Carlsbad, CA) was used for emulsion PCR and templated bead enrichment. Enriched beads were chemically bound to treated SOLiD flow cells, then sequenced using the SOLiD (sequencing by ligation) pairedend sequencing process. Some sets of RNA samples were prepared for sequencing on a SOLiD Wildfire instrument (Life Technologies, Carlsbad, CA), eliminating the need for emulsion PCR and library bead enrichment. Barcoded SOLiD libraries were prepared as
before, and then Wildfire adapters were ligated to the SOLiD libraries. Calibrated concentrations of these Wildfire libraries were pipetted into the Wildfire flow-chip. On-slide isothermal template walking produced defined, single insert colonies of appropriate size and density for SOLiD Wildfire paired end sequencing.

**Sequencing experimental design**

Our goal was to sequence RNA from 10 brain regions in 10 subjects, at sufficient depth to detect a wide range of transcript expression, including non-coding RNAs. The scope of the project required multiple sequencing runs. To account for sequencing batch effects, the sequencing runs were designed to optimize comparisons both between samples, and between regions. To facilitate these comparisons, nine of the brain regions from one subject were barcoded, combined, and sequenced together in the same run. The tenth brain region (BA46) from every subject was separately barcoded, and these barcoded samples from all ten subjects were sequenced together in one run. Of the 11 total runs, 8 were processed with Wildfire technology, and 2 runs were sequenced for the forward reads only. Several sets were replicated to account for changes in sequencing technology and to increase read coverage (Average Pearson correlation of libraries within a set across any replicates: MB52 = 0.70, MB160 = 0.94, MB147 = 0.98, MB100 = 0.85, MB11 = 0.86).

**Data processing**

Sequence Alignments. RNAseq data were aligned to a modified version of the Genome Reference Consortium human genome build 37 (hg19, Feb. 2009) containing IUPAC ambiguous nucleotide characters for each annotated SNP in dbSNP 135 with alignment performed using SOLiD LifeScope™ Genomic Analysis Software v2.5.1 (Life Technologies Carlsbad, CA). Gene features were annotated using a combination of GENCODE v18 [33] annotation plus non-identical transcripts annotated by Incipedia v2.1 [34]. The combination of these annotations provides a richer set of coding and non-coding transcript types. The bedtools suite [35] was used to generate non-overlapping exonic, intronic, and intergenic annotation. The exonic regions for each transcript were merged and subtracted from the whole gene length to extract intrinsic regions. Whole genes were subtracted from the genome to identify intergenic regions. With these regional annotation sets, bedtools coverage was used to generate a count for each region and the proportion of coverage.

**Gene expression**

Cufflinks v2.1.1 [36] was implemented to estimate gene specific abundances. Expression level is reported as FPKM (Fragments Per Kilobase per Million reads) which normalizes the number of reads within a gene by the number of fragments per kilobase of exon and million mapped reads for a given sample. Expression measurements were quantified strictly based on GENCODE v18 [33] gene annotation combined with the additional transcripts present only in the Incipedia non-coding RNA database [34]. The combination of these two annotation sets allowed for the consideration of a wide variety of protein coding and non-coding transcripts. Multi-read correction was applied to improve the expression estimates when considering multimapped reads. Whole gene expression measurements were based on the sum of the expression of all exons of all annotated isoforms at a gene locus.

**Entropy based analysis of stably expressed RNAs**

Comparing results from multiple RNAseq runs requires means for normalization, accounting for batch effects and sample-to-sample variability. Stably expressed genes can serve to account for these confounding effects. Genes with stable expression across brain regions and subjects were identified as possible reference RNAs for normalizing expression levels of other RNAs using the following information-theoretic approach. First we searched for well-expressed genes (>3 FPKM) with a flat expression profile over the set of all available brain regions. Second, we have looked for stably expressed gene in each regions separately, taking the expression vector of each gene over the available individuals. For both genes with stable expression across all regions and genes with stable expression within a region, we have treated every expression vector as a trial for a multinomial distribution, using Shannon entropy function as a measure of uniformity. For any probability distribution, entropy is always positive and attains its maximum (over the space of all discrete distributions with given support) on the uniform distribution [37]. Third, we have searched for well-expressed genes with reproducible expression patterns over the available individuals. We make our predictions more robust to inter-individual variability by using the following re-sampling-based procedure: we select m random subsets of k individuals (taking k = 2,3,...,9 and m between 10 and 50 dependent on the choice of k) and compared the selected k expression vectors (of a single gene over the available tissues). To compare expression vectors we have used the approach proposed by Rempala and Seweryn [38] and quantified the overlap between the k columns in a contingency table by calculating the I-index. The I-index is an overlap measure as a function of the mutual information; it is always positive and attains its maximum (which equals 1) if any of the columns in a contingency table are linearly dependent. We have selected the genes with
Compilation of nicotine related genes

Genes related to nicotine exposure and addiction were gathered from several online sources. 1196 genes with expression differences related to smoking, nicotine, and tobacco were selected from the Expression Atlas (ebi.ac.uk) [39]; 60 genes with SNPs associated with smoking, smoking cessation, and tobacco use disorder were identified from GWAS and NCBI databases by PheGenI (ncbi.nlm.nih.gov/gap/phegeni) [40]; 40 genes with connections to nicotine and tobacco use were listed in PharmGKB [41]. Liu et al. proposed a list of 587 genes relating to nicotine, with a prioritized set of 220 genes [26]. A study by Tyndale et al. identified 58 genes relating to smoking cessation [42]. Of these a total of 1789 unique genes were mapped to GENCODE gene annotation.

Differential RNA expression and interpretation

The read count per gene for analysis was generated by featureCounts from the subread package [43]. The primary alignment for each read was used in counting. Differential expression analysis was performed by edgeR [44] and RUVseq [45]. RUVseq used internally identified 200 ‘invariable’ genes to reduce variability between samples and estimated a term for edgeR’s glm analysis. Differential expression was performed pairwise between regions and between smokers and nonsmokers within a region. To be included in analysis between regions, a gene needed >10 reads in >8 samples. To be included in analysis between smokers and nonsmokers, we required a gene to have an expression of ≥2 counts per million (reads per gene divided by million aligned reads) in all subjects included in a comparison. GO term enrichment was performed with the ToppFun application of the ToppGene [46] suite to identify molecular and biological processes over-represented in the gene list. Custom pathways were aligned with Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity) to find connections between RNA molecules and smoking/nicotine.

SNP calling and allele specific expression

Genotyping was performed on Illumina GeneChip on genomic DNA for each of the 10 subjects. To overcome a bias in alignment of short reads, where the reference allele reads are preferentially aligned over reads with the variant allele, we used a genomic reference containing IUPAC codes for SNPs in dbSNP. This approach limits consideration to known SNPs, but equalizes the alignment rate of reads containing known variants. Default settings of samtools mpileup [47] were applied to each RNA library individually to make SNP calls only for heterozygous SNP locations identified by GeneChip. Gene bins were created for all annotated genes from the combined GENCODE and Incpedia annotation, taken as 1 Kb upstream and 1 Kb downstream of each annotated gene (recognizing that regulatory variants can be much more distant). Overlapping genes containing exactly the same SNPs will have the same AEI fold change value. For the analysis of allelic mRNA expression differences, SNPs were assigned to bins and could belong to multiple bins in the case of overlapping regions. A set of filters was applied to reduce the number of false positives arising from noise of the RNAseq data, guided by earlier quantitative estimates [24]. We retained SNPs belonging to at least one bin and having an assigned rs number based on dbSNP build 135, and filtered for a combined read coverage of 10 reads (reference allele count plus variant allele count). For the second level of filtering, we require a SNP to be called in 3 or more regions of the same subjects. Out of these, we selected genes that had two or more SNPs called within a sample from a tissue, to obtain at least two independent allelic ratio measurements for any given RNA. To meet this condition, we required the distance between SNPs in a gene to be greater than the length of a single read (>50 bases). For each gene, we calculated the average allelic ratio and read depth of coverage. RNAs with likely allelic expression imbalance greater than 2, regardless of individual SNP differences, were required to have an allelic ratio greater than twofold at the lower bound of the 95 % confidence interval. For a list of the highest confidence SNPs, we further filtered by an average read depth per SNP of 30 reads.

RNA isoform analysis

Cufflinks v2.2.1 [36] was implemented to estimate isoform specific abundances using cuffquant to quantify expression, and cuffnorm to normalize the expression levels for RefSeq annotated isoforms downloaded from the UCSC genome browser in refFlat format. RefSeq was used for isoform quantitation because of its simplicity in transcript annotation compared to GENCODE. Isoform fraction is calculated as the expression of a single isoform divided by the sum of expression of isoforms assigned to a gene. Genes were considered when having ≥5 FPKM in at least 40 libraries. To detect genes generating different isoform patterns in different brain regions we sorted genes with multiple isoform by the number of tissues with an isoform average outside the 99 % confidence interval generated from all samples. This provided a simple measure of how much individual regions deviated from the average.
Results

Sequence read distribution across genomic regions

Brain tissues were divided into 11 sequencing sets, with 10 sets including 9 regions for a single subject and 1 set including 9 subjects for one region. Replicate sets correlated well so the sequence reads were merged (Pearson correlation between replicate sets, reported as average across libraries within a set: MB52 = 0.70, MB160 = 0.94, MB147 = 0.98, MB100 = 0.85, MB11 = 0.86). Additional file 1: Table S1 provides complete sequencing and mapping information. After alignment with Lifescope, 60–80% of forward reads and 40–70% for reverse reads were aligned to genomic sequence. Separating aligned sequences by exonic, intronic, and intergenic regions yields estimates of read number generated from each region illustrated in Fig. 1. On average, 52, 34, and 14% of reads aligned to exonic, intronic, and intergenic regions, respectively. These read counts are independent of the length of a gene locus or region. 15% of reads aligned to the mitochondrial chromosome, and 2% aligned to the three major ribosomal transcripts (18S, 28S, and 5.8S; reduced over 95% with the NuGen kit). To account for length of genomic regions, we estimated RPKM (reads per kilobase per million total reads of a sample) per region by dividing total reads per genomic region by the total genomic length (kb) of each region annotated by GENCODE and Incipedia including both coding and non-coding RNAs, yielding an average expression of 4.2 RPKM, 0.2 RPKM, and 0.1 RPKM in exonic, intronic, and intergenic regions, respectively. By the same criteria, mitochondrial genes are highly expressed.

Identification of genes with consistent expression across regions and samples

We first identified RNAs stably expressed across multiple tissues and subjects. These genes are useful as “normalizing” genes to facilitate comparison between samples. Mathematical modeling served to characterize global transcript expression patterns. Shannon entropy-based analysis was used to identify the RNAs that were similarly expressed across all brain regions in any individual, and those stably expressed in all regions in all 10 individuals (Additional file 1: Table S2). Additional file 2: Figure S1 shows the average expression of all invariable genes in the 4 GTEx brain regions that overlap the current survey confirming the expectation that these genes have a small range of expression across different brain regions. GO term analysis indicates that these “stable” and “invariable” genes are involved in various biological processes, such as, chromatin modification, (BAZ1B, CHD2 and MECP2); mRNA processing (SRRM1, RBM25, CPSF7) and neuronal cell adhesion (CDK5R1, NLGN2, ASTN1). We propose that any of these genes could serve to normalize expression profiles, and used the genes to remove unwanted variation during differential expression analysis.

![Fig. 1 Read alignment across genomic regions. Presents the percentage of aligned reads falling within genomic regions of different types–exonic, intronic, and intergenic as annotated by GENCODE and Incipedia; any reads aligning to the mitochondrial chromosome; and ribosomal reads filtered by during alignment (18S, 28S, and 5.8S only)](image_url)
Region-selective expression of RNA classes

To test how RNA transcripts tend to be expressed across region types, we generated counts of the number of times an RNA is detectable across the 10 regions and stratified this by transcript-type based on GENCODE-Incipeida annotations. Detection within a region was defined as expression greater than 2 FPKM in two or more subjects. This arbitrary cutoff serves as an example to assess relative expression selectivity for various RNA classes, leaving out relevant transcripts with low expression. The relative contributions of reads aligned to protein coding, lncRNA, pseudogenes, and processed transcripts to regional expression patterns is shown in Fig. 2. The mRNAs represent by far the largest group of these relatively robustly expressed genes (10,680), followed by lncRNAs (838). lncRNAs include transcripts labeled as lincRNA, antisense, sense intronic, sense overlapping, and those added from Incipedia. Among the protein coding mRNAs, the majority is widely expressed, whereas other transcripts, in particular the lncRNAs, display a more selective expression pattern, possibly suggesting distinct functions of a relatively small set of non-coding RNAs required in various brain regions.

To explore the number of detectable RNA transcript types across the brain, we calculated the average expression of each gene across all subjects. For further analysis, we created bins of expression levels ranging from 2 FPKM to 5000 FPKM (Fig. 3), leaving out RNAs with low expression levels (<2 FPKM). Read counts attributable to non-coding transcripts are generally lower than read counts aligned to protein coding transcripts. Half of expressed protein-coding RNAs are detectable with >5 FPKM, whereas for lncRNA only 35 % of expressed RNAs are detectable at the 5 FPKM level. Hence, only a small number of ncRNAs displays robust expression, but these could be instrumental in defining specific functions across brain regions.

Differential RNA expression across brain regions and subjects

RNAs with divergent expression patterns between brain regions and subjects likely reflect dynamic processes. To be included in analysis, we used RUVseq suggested filtering requiring >10 reads in >8 samples (at least half of all samples included in a comparison). FDR correction was made only for genes included in the analysis. In region to region comparisons, 8 to 10 subjects were included per category. We performed differential gene expression analysis with edgeR together with RUVseq in order to use invariant genes to reduce unwanted variation.

Table 1 shows the number of RNAs significantly (FDR ≤ 0.05) differentially expressed between every combination of region pairs. This analysis revealed relative similarities between regions - BA10, BA22, BA24, and insula (0–342 differentially expressed (DE) genes); amygdala and hippocampus (250 DE genes); and putamen, cerebellum, and raphae nucleus (0–402 DE genes). Transcriptional differences between four pairs of brain regions showing highest dissimilarities of expression profiles are illustrated in Additional file 3: Figure S2. Complete list of DE genes for each pair of brain regions is shown in Additional file 1: Table S3. The majority of DE genes stratified by RNA type are protein coding, while 20 % come from non-coding RNAs (including...
IncRNA, lincRNA, antisense, processed transcripts, etc.) and 9.5 % from pseudogenes. This result reflects the more robust expression of numerous protein coding RNAs but highlights the potential importance of a small set of non-coding RNAs in the difference between brain regions.

Differential RNA expression between smokers and non-smokers

We again performed differential gene expression analysis with edgeR which uses a Poisson model. With an analysis performed for each brain region, we searched for genes differentially expressed between smokers and non-smokers. For differential expression analysis, we considered only RNAs with CPM (counts per million total reads) > 2 in every tissue sample used in a comparison. For any given comparison, this left 8000 to 14,000 genes for analysis. In all tissues except BA46 and raphae nuclei (one subject missing for each), 5 smokers and 5 nonsmokers were included. BA46 from one smoker displayed a highly variable expression profile but analysis with RUVseq was able to reduce the variability seen in this sample allowing for its inclusion. Under these experimental conditions, we did not expect to detect many transcriptome-wide significant differences, and therefore, also relied on previously identified candidate genes. As a result of the small sample size and tendency for batch effects, most regions had few to no genes with

Table 1 Differentially expression between tissues

| BA22 | BA24 | BA46 | Insula | Amygdala | Hippocampus | Post. putamen | Cerebellum | Raphae |
|------|------|------|--------|----------|-------------|--------------|------------|--------|
| 4    | 11   | 872  | 114    | 1281     | 1612        | 1801         | 4315       | 2876   |
| 43   | 62   | 119  | 1761   | 1895     | 1891        | 3577         | 2791       | BA22   |
| 106  | 0    | 1123 | 1655   | 2252     | 4778        | 3548         | BA46       |
| 342  | 1114 | 1794 | 1193   | 2828     | 2176        | 51           | Insula     |
| 521  | 1322 | 1820 | 4415   | 3155     | 2256        | Amygdala     |
| 251  | 797  | 3606 | 2256   | 1714     | 402         | Cerebellum   |
| 827  | 3206 | 1714 | 402    | 51       |             |              |

The number of genes are listed found to be differentially expressed (FDR ≤ 0.05) between pairwise tissue comparisons. FDR correction was made for genes included in analysis based on detectability.
transcriptome-wide significance at either level, while 56 genes were identified as differentially expressed in BA46 with FDR ≤ 0.1, including several non-coding genes (RP11-294 K24.4, LINCO0617, AC144521.1) and pseudogenes (RP11-768G7.1, GJA1P1). An additional 39 genes in BA22, 2 genes in the insula, and one gene in the raphae nucleus were significant with FDR ≤ 0.1 (see Additional file 1: Table S3 for all genes and FDR levels). Focusing on known nicotine related genes in BA46, 14 genes were significantly different with FDR ≤ 0.1, and 7 of these retained significance at FDR ≤ 0.05. In BA22, 6 out of 39 genes with FDR ≤ 0.1 were nicotine related. In raphae nuclei, a single significant gene was nicotine related (SEMA3C FDR = 0.05). All genes with FDR ≤ 0.1 are listed in Additional file 1: Table S4 and nicotine related genes are marked with an asterisk. Functional enrichment analysis with toppgene targeting genes relating BA46 to smoking found 13 genes related to “response to abiotic stimulus” (GO:0009628, FDR B&H = 4E-3), such as: VEGFA, HIF3a, TP53BP2 and IGFBP7, 10 genes relating to “behavior” (GO:0007610, FDR B&H = 8E-3), such as: CIART, GPR37 and PTN; 11 genes related to transmembrane transport (GO:0055085 FDR B&H = 3E-2) including: ATP13A4, ATP1A2, SLClA2 and SLClA2 (Table 2).

Pathway analysis of RNAs with differential expression between smokers and non-smokers
To understand how the differentially expressed genes from BA46 relate to smoking and nicotine, we built a custom pathway with the Ingenuity Pathway Analysis (IPA) package. Differentially expressed genes were added to a custom pathway, together with the terms “nicotine,” “smoking,” and all smoking related molecules. Connections were made between differentially expressed genes and the additional molecules using default IPA options. A prominent pathway in this analysis focuses on VEGFA, with genes more than two links from VEGFA removed (Additional file 4: Figure S3). Differentially expressed RNAs involved in this pathway, highlighted in green, were all higher in non-smoker tissues (BA46).

| Gene          | Gene information                                      | GO term                                           |
|---------------|-------------------------------------------------------|---------------------------------------------------|
| APOLD1        | Apolipoprotein L domain containing 1                  | Response to abiotic stimulus                      |
| ATP1A4        | ATPase type 1A4                                        | Transmembrane transport                           |
| ATP1A2        | ATPase, Na+/K+ transporting, alpha 2 polypeptide       | Behavior / response to abiotic stimulus / transmembrane transport |
| CIART         | Circadian associated repressor of transcription       | Behavior                                           |
| GJA1          | Gap junction protein, alpha 1, 43 kDa                 | Behavior / response to abiotic stimulus / transmembrane transport |
| GPR37         | G protein-coupled receptor 37 (endothelin receptor type B-like) | Behavior                                           |
| HIF3a         | Hypoxia inducible factor 3, alpha subunit              | Response to abiotic stimulus                      |
| IGFBP7        | Insulin-like growth factor binding protein 7           | Response to abiotic stimulus                      |
| MLC1          | Megalencephalic leukoencephalopathy with subcortical cysts 1 | Response to abiotic stimulus / transmembrane transport |
| PLOD2         | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2    | Response to abiotic stimulus                      |
| PREX2         | Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 | Behavior                                           |
| PTN           | Pleiotrophin                                          | Behavior                                           |
| S1PR1         | Sphingosine-1-phosphate receptor 1                     | Behavior                                           |
| SDC2          | Syndecan 2                                            | Response to abiotic stimulus                      |
| SDC4          | Syndecan 4                                            | Response to abiotic stimulus                      |
| SLC14A1       | Urea transporter/Kidd blood group                     | Transmembrane transport                           |
| SLC1A2        | Glial high affinity glutamate transporter             | Transmembrane transport                           |
| SLC1A3        | Glial high affinity glutamate transporter             | Behavior / response to abiotic stimulus / transmembrane transport |
| SLC4A4        | Sodium bicarbonate cotransporter                     | Transmembrane transport                           |
| SLC5A11       | Sodium/inositol cotransporter                        | Transmembrane transport                           |
| SLC7A11       | Anionic amino acid transporter light chain, xc- system | Transmembrane transport                           |
| SLC01C1       | Solute carrier organic anion transporter              | Transmembrane transport                           |
| TP53BP2       | Tumor protein p53 binding protein 2                   | Response to abiotic stimulus                      |
| VEGFA         | Vascular endothelial growth factor A                  | Behavior / response to abiotic stimulus           |

Two GO terms were enriched from genes with significant (FDR ≤0.1) differential expression between smokers and nonsmokers in BA46.
Analysis of RNA isoform expression across brain regions

A majority of genes generate multiple RNA isoforms that often differ between tissues. To detect characteristic differences in brain region-selective expression, we ranked genes yielding isoform ratios with largest variability between regions (averages outside the expected 99% confidence interval). Table 3 lists genes with the highest scores, while Fig. 4 highlights neurexin-3 (encoded by NRXN3) as an example. A complete record can be found in Additional file 1: Table S5 of the average isoform fraction of all genes considered across brain regions. The non-coding versions have at least one unique exon that does not overlap with coding versions of NRXN3. Alignment to these isoform-specific exons direct analysis of the expression levels. The raphae nuclei, cerebellum, and posterior putamen tend to express mostly the short NRXN3 transcript dup5 isoform while other tissues express mostly full length NRXN3 dup0. The short isoform dup5 lacks a large portion of the 5′ end and likely supports different functions, annotated as non-coding RNA lacking known coding potential. The non-coding versions have at least one unique exon that does not overlap with coding versions of NRXN3. Alignment to these isoform-specific exons direct analysis of the expression levels.

Quantification of expression is sensitive to the read assignment method applied, such as the one used by Cufflinks, to distribute reads to expressed regions of isoforms over the whole gene. While Cufflinks...
probabilistically assign reads to isoforms and is widely accepted as an accurate expression quantification method, one could focus on local differences, i.e., what exons are being included or excluded, and consider a custom set of isoforms based on expression within the working dataset. One option within cufflinks is to quantify the expression within the dataset and generate a gene annotation file based on that data; however, this approach can merge genes that should be kept separate. To test whether the results change when using only well expressed isoforms for quantification, we reran cufflinks with NRXN3_dup0 and NRXN3_dup5 as the only two isoforms for NRXN3. For those tissues with a high percentage of the full length NRXN3, 13 % of isoforms are expressed as dup5 from an alternative start site generating a shorter NRXN3 RNA. For the raphae nuclei and cerebellum, this percentage goes up to 65 %. When limiting the gene annotation set to dup5 and dup0 isoforms, most reads originally assigned to minor isoforms and dup4 were assigned to dup5, changing the isoform fractions marginally.

**SNP calling and allele-selective RNA expression, or allelic expression imbalance (AEI)**

Several filters were employed to select SNPs contributing to a measure of allelic expression imbalance across a gene. Requiring a 95 % confidence level as the lower bound to the AEI ratio of SNPs within a gene for a given subject/region, an average of 24 RNAs displayed a robust signature of possible allelic expression imbalance (AEI) per region, with ~1600 genes represented across all regions and subjects (1.4 K protein coding, 177 non-coding, 22 pseudogenes). These results point to the presence of frequent regulatory variants affecting the expression of all RNA classes. Additional file 5: Figure S4 shows a scatter-plot of the average magnitude of the allelic RNA ratio compared to the average read depth for SNPs contained in the gene (with a twofold allelic RNA ratio above the 95 % CI as the cutoff). Genes with more extreme imbalanced ratios tend to have lower read depth, which decreases precision of measuring allele specific expression. On the basis of this graph, we chose an arbitrary read cutoff of 30 reads per SNP for the purpose of the present analysis.

With a stringent read filter of 30 reads per SNP and twofold AEI ratio, we detect 443 genes with likely AEI in any region such as Huntington’s Disease-associated: ELMO1, NTRK2, WNK1 and associated with Schizophrenia: NTRK2, PIK3R1 and RTN4. Table 4 contains the top 20 genes with AEI detected in any sample, sorted by magnitude of AEI ratios and by brain region. A complete listing is found in Additional file 1: Table S5. Most of these genes have detectable AEI in 1 tissue in 1 sample as detection of AEI depends on expression level. At the stringent 30 read filter, 6 genes were detected with AEI in more than one subject of the same brain regions, a finding likely associated with high minor allele frequency of a regulatory variants. Table 5 shows these 6 genes and results from eQTL and GWAS databases. Of these 6 genes, LPARI, PSD3, and GNAS are associated with brain-related phenotypes (alcoholism, memory, and brain waves), and LPARI, PSD3, GNAS, and SRPK2 with eQTLs annotated in GTex or PheGenI in any human tissue (brain regions are not well represented in GTEx). It is apparent that these genes carry frequent regulatory variants with robust effects on RNA expression levels. We are currently
developing mathematical and statistical methodologies for examining the landscape of allelic expression ratio to extract instances of less robust AEI.

Gene expression confirmation
RNA-seq values of selected genes were orthogonally verified using Taq-Man qRT-PCR gene expression measurements. Real-time PCR was used to evaluate expression levels of three of the invariant genes applied to normalize the sequencing reads (AGO1, SPEN, SRSF11 each expressed at different FPKM levels) and also to re-evaluate the expression profiles of three nicotine related genes with variable expression (HIF3A, SLC1A3, NRXN3). Expression levels were measured by qRT PCR in all available brain regions of each sample. Using a log transformation, the overall pearson correlation of these measurements was 0.92. See Additional file 6: Figure S5 for a scatterplot of the comparison.

Data sharing
The data supporting the results of this article are available in the GEO repository (accession ID: GSE68559 link:

### Table 4: Top 20 AEI per tissue

| Tissue          | Gene     | AEI ratio | Avg ± S.D. | Avg SNPs per gene per sample | GTex eQTL         | PheGenI eQTL         | PheGenI association |
|-----------------|----------|-----------|------------|-------------------------------|-------------------|----------------------|---------------------|
| Amygdala BA10   | SNHG14   | 1         | 2.8 ± 0.7  | 2                             | Whole blood       | Brain cerebellum     | Alcoholism           |
|                 | BCAP29   | 2         | 3.4 ± 0.7  | 2                             | Brain pons        | Memory               |                     |
|                 | C7orf41  | 3         | 2.8 ± 0.4  | 2                             | Liver, lymphoblastoid | Brain waves         |                     |
|                 | ATP6V1G2 | 4         | 3.4 ± 0.7  | 2                             | Whole blood, esophagus | Lymphoblastoid |                     |
|                 | SLC8A1   | 5         | 2.8 ± 0.4  | 2                             |                    |                      |                     |
|                 | ERV3-1   | 6         | 2.8 ± 0.4  | 2                             |                    |                      |                     |
|                 | RP11-785H5.1 | 7     | 3.4 ± 0.7  | 2                             |                    |                      |                     |
|                 | CD24P4   | 8         | 2.8 ± 0.4  | 2                             |                    |                      |                     |
|                 | CCT5     | 9         | 2.8 ± 0.4  | 2                             |                    |                      |                     |
|                 | GSTA4    | 10        | 3.4 ± 0.7  | 2                             |                    |                      |                     |
|                 | NDRG3    | 11        | 2.8 ± 0.4  | 2                             |                    |                      |                     |
|                 | SNHG14   | 12        | 3.4 ± 0.7  | 2                             |                    |                      |                     |
|                 | RALGAP8  | 13        | 2.8 ± 0.4  | 2                             |                    |                      |                     |
|                 | NDFG4    | 14        | 3.4 ± 0.7  | 2                             |                    |                      |                     |
|                 | NDFN1    | 15        | 2.8 ± 0.4  | 2                             |                    |                      |                     |
|                 | NDFN2    | 16        | 3.4 ± 0.7  | 2                             |                    |                      |                     |
|                 | NDFN3    | 17        | 2.8 ± 0.4  | 2                             |                    |                      |                     |
|                 | NDFN4    | 18        | 3.4 ± 0.7  | 2                             |                    |                      |                     |
|                 | NDFN5    | 19        | 2.8 ± 0.4  | 2                             |                    |                      |                     |
|                 | NDFN6    | 20        | 3.4 ± 0.7  | 2                             |                    |                      |                     |

After restricting the list of genes with AEI to those with >30 reads per SNP averaged across gene, the list for each region is sorted by average AEI fold-change.

### Table 5: Genes with AEI in 2 samples in a region

| Region            | Gene     | AEI ratio | Avg ± S.D. | GTex eQTL | PheGenI eQTL | PheGenI association |
|-------------------|----------|-----------|------------|-----------|--------------|---------------------|
| BA10              | AKAP12   | 3.7 ± 0.6 | 6          | Whole blood | Brain cerebellum | Alcoholism           |
| BA22              | LPAR1    | 3.3 ± 0.7 | 3          | Brain pons | Memory        |                     |
| BA46              | PSD3     | 3.4 ± 0.7 | 2          | Liver, lymphoblastoid | Brain waves |                     |
| Cerebellum        | GNAS     | 2.8 ± 0.4 | 2          | Whole blood, esophagus | Lymphoblastoid |                     |
| Hippocampus       | SRPK2    | 3.6 ± 0.7 | 2          |                    |              |                     |
| Raphae nucleus    | PDE4DIP  | 3.4 ± 0.8 | 3          |                    |              |                     |

Genes with allelic expression imbalance in 2 subjects in the same brain region after stringent filtering of 30 reads of coverage. Listed is the average and standard deviation of the AEI fold change for each gene and the average number of SNPs contributing to the AEI signal for each gene per sample. Genes were checked against public databases for eQTLs and SNP associations.
Discussion

We present here the results for RNAseq analyses in ten human brain regions from ten subjects, five with a history of smoking and five controls. Owing to the preparation of sequencing libraries with both poly-dT and random hexamer primers, all RNA classes are detected, thereby, providing additional detail not available in previous studies of brain transcriptomes, such as transcript isoforms, non-coding RNAs, and allelic ratios as indicators of regulatory variants. A first analysis of differential gene expression between smokers and non-smokers was guided by previous results, as the number of subjects is limited for an independent analysis.

Abundance and distribution of protein coding and non-coding RNAs

With both random hexamer and poly-dT priming, we covered all RNAs at least 200 bases long, regardless of poly-adenylation status. Wide-ranging transcription from a considerable portion of the genome has led to the discovery of tens of thousands of non-coding RNAs with diverse functions. Our results in human brain regions illustrate the robust expression of a large number of protein coding mRNAs compared to non-coding RNAs, even though only 1.2 % of the genome consists of coding exons. More protein coding genes are expressed across all 10 regions than non-coding RNAs and pseudogenes. This finding suggests lncRNA, pseudogenes, and processed transcripts are more region-specific than protein coding transcripts and could support distinct functions critical to specific tissues. Preliminary analysis not reported here shows that gene networks derived from the RNA expression patterns may be strengthened with the inclusion of non-coding RNAs with ncRNAs serving as relays in protein-coding RNA networks but further work is needed (unpublished results). The brain region RNAseq data provided here appear to be useful for network analyses and defining potential functions of ncRNAs.

Transcriptome analysis of brain regions from smokers and controls

Our study was designed to complement previous transcriptome analyses, and to serve as a starting point for extended analysis of a larger cohort, or to study the isoform expression profiles of known candidate genes. The identification of differentially expressed genes, either from tissue to tissue comparisons or from smoker vs non-smoker, highlights the effect of sequencing batch on gene expression, as a confounding factor. Regions from BA46 were sequenced in the same run and are best suited for comparisons within the region between smokers and nonsmokers. Conversely, the other nine regions were sequenced in one run for each subject separately, leading to a batch effects between regions. Without added normalization, these nine regions are best suited for tissue to tissue comparisons as they have the same batch biases. Here we have extracted those genes with similar expression across all regions, and in addition those that are invariant between subjects, employing a Shannon entropy-driven analysis. We propose that these genes can serve broadly as genes for normalization of RNAseq data acquired from heterogeneous tissues such as brain. Using these invariant genes with RUVseq to remove unwanted variation, we were able to overcome batch effects leading to enhanced difference between BA46 and other tissues, and yielding differential gene counts expected from biological similarity between brain regions.

A number of genes were differentially expressed between smokers and non-smokers, detectable mostly in brain region BA46, including WiFi1, CX3CR1, and APOLD1. Using Ingenuity pathway analysis with nicotine as the central theme, several of the differentially expressed RNAs were found to connect directly or indirectly to VEGFA, which in turn connects to smoking pathways through VCAM1 and DRD2. VEGF is a growth factor involved in angiogenesis, vasculogenesis, and endothelial cell growth (UniProtKB/Swiss-Prot), while previous studies report various associations with nicotine and smoking. Cigarette smoke was found to reduce VEGF levels in human umbilical vein endothelial cells [48], whereas two other studies failed to detect a correlation between VEGF plasma levels and smoking status [49, 50]. Smoking was further associated with VEGF receptor expression [49] and abnormal endothelial function [50]. Moreover, VEGF may have a protective role in ischemia and stroke [51, 52], potentially counteracting the deleterious effects of smoking. Neuroprotective effects of VEGF under ischemia had been demonstrated in rat neurons [51]. Further studies are needed to follow up on the role of differentially expressed genes in smokers versus non-smokers.

Differential expression of RNA isoforms across brain regions

Our RNAseq database is well suited to detect RNA isoforms that occur at nearly all gene loci. Here we have focused on an analysis of genes yielding isoforms with distinct distribution patterns between brain regions. We use neurexin-3, encoded by NRXN3, as one example of substantial differences between tissues. Whole gene expression of NRXN3 in brain regions was robust, ranging from 20 to 43 FPKM. Raphae nuclei and cerebellum expressed...
more NRXN3_dup5 isoform while other tissues express higher amounts of NRXN3_dup0 full length mRNA. Samples from the posterior putamen show a mixture of either more dup5 or more dup0 isoforms, likely due to differences in cellular heterogeneity or genetic factors. Both isoforms are labeled as “noncoding” by RefSeq and “nonsense mediated decay” by ensembl suggesting it may play a role in reducing erroneous gene expression. As neither isoform is thought to express a protein, one must take isoform distribution across brain regions into account in biological studies to avoid erroneous conclusions. Looking at the exons unique to the dup0 and dup5 isoforms, not present in any coding version, it appears that both isoforms are robustly and differentially expressed between brain regions into RNA. Moreover, we identified AEI for NRXN3 RNA in three tissues —insula, amygdala, and BA46 (each for a different sample), while no eQTLs are listed for NRXN3 in GTEx; this may result from averaging all isoforms to yield a composite mRNA level. Our results can lead to the identification of regulatory variants in NRXN3.

Comparing average whole gene expression of NRXN3 for 4 brain regions (amygdala, BA24, cerebellum and hippocampus) present in both our data set and in the Genotype-Tissue Expression (GTEx) project, yielded a strong correlation with $r = 0.92$. In both datasets, NRXN3 is expressed in higher amounts in the cerebelum compared to other regions. For a direct comparison between the OSU and GTEx NRXN3 isoform expression, we adopted the transcript profile annotated in GTEx. In our dataset, the three most prominent isoforms were ENST00000428277.2, ENST00000555387.1, and ENST000005554738.1, while in the GTEx brain regions, ENST00000428277.2 accounts for approximately 80 % of NRXN3 mRNA compared to ~30 % in the OSU brains. This difference is likely due to library preparation and poly-A selection employed by GTEx. If we focus on the latter two isoforms, the ratio of these two isoforms favors ENST000005554738.1 in both GTEx and OSU in the cerebellum and favors ENST00000555387.1 in the other 3 overlapping regions. ENST000005554738.1 corresponds to NRXN3_dup5, and ENST00000555387.1 corresponds to NRXN3_dup0 confirming the results shown in Additional file 7: Figure S6.

**Allelic RNA expression**

Using strict filtering criteria, we identified a group of genes with allelic expression imbalance in any sample from different brain regions. The stringent filters used here detect only the most striking signals of allelic expression imbalance. The combination of these parameters with large scale genotyping with GeneChip of the gDNA provides strong evidence a variant is truly heterozygous and that a finding of allelic RNA expression imbalance (AEI) is justified. This approach yielded a list of genes likely to be under regulatory influence where one copy of the gene is preferentially expressed. Given that only ten subjects were analyzed, the minor allele frequency of any regulatory variant can vary substantially over a broad range. However, this range is much narrower when 2 of 10 subjects display AEI for any given gene, implying a mean allele frequency of ~10 %. We detect 6 genes with AEI in more than one subject, indicating that a frequent regulatory variant is present with substantial effect on expression (Table 4). Four of these genes had been previously identified as containing eQTLs, i.e., variants that are associated with mRNA expression in various tissues, providing independent confirmation that these genes are under regulatory influence in other tissues. Three genes were found to be associated with clinical phenotypes in GWAS studies (Table 4). \(LPARI\) encodes a receptor for lysophosphatidic acid and has been associated with alcoholism (rs509276, located upstream of \(LPARI\); \(p = 2.5e-5\) in Collaborative Study on the Genetics of Alcoholism COGA [53]). \(PDS3\) (encoding Pleckstrin and SEC7 domains-containing protein 3) is a cancer risk gene that has been associated with memory functions (rs901732, intronic, \(p = 3.7e-8\); rs1386687, intronic, \(p = 7.9e-6\); Framingham Heart Study [54]). Lastly, \(GNAS\) (encoding the Gsa subunit of stimulatory G proteins) is a critical signaling molecule in the activation of adenylyl cyclase and has been associated with numerous disorders and phenotypes (see OMIM). A detailed analysis of all cases of AEI is ongoing.

**Conclusions**

RNA sequencing identifies distinct and consistent differences in gene expression between brain regions. Non-coding RNAs are also differentially expressed between brain regions and may play a role in regulation of gene expression and functional differentiation of the different brain areas. Smoking affects coding and non-coding transcript expression in BA46 in a number of genes related to nicotine exposure. The purpose of this report was to provide an overview of the data source created by sequencing 10 brain regions of 10 subjects. We present here patterns of expression of various types of RNA, differential expression between tissues, differences in the expression of RNA isoforms, and detection of allelic expression analysis identifying genes under regulatory genetic influence.

**Additional files**

Additional file 1: Table S1. Sequencing and mapping statistics. Listed are the sequencing details and mapping statistics for the presented data. Sequencing sets varied in the number of lanes per run, sequencing technology, and inclusion of paired reads. For sets with replicate runs, the number of lanes for each run and the sequencer technology are separated by slashes. Some replicate runs were generated under different sequencing conditions (SOLID500 technology vs wildtype technology) and this is indicated when appropriate. Table S2. Normalizing genes identified by mathematical modeling. 2a Top 200 invariable genes. Lists
Table S3. Differentially expressed genes between brain regions. Lists all significantly (FDR ≤ 0.05) differentially expressed genes between any two brain regions identified by RUVseq after removing unwanted variation using invariant genes. Table S4. Genes differentially expressed between smokers and nonsmokers. Lists the genes found to be differentially expressed between smokers and nonsmokers (FDR ≤ 0.1). Genes previously implicated in nicotine or smoking are marked with an asterisk. Table S5. Isoform fraction across brain regions. Lists the average isoform fraction across brain regions for genes passing expression level filters. Genes were considered when having ≥ 5 FPKM in at least 40 libraries. To detect genes generating different isoform patterns in different brain regions we sorted genes with multiple isoform by the number of tissues with an isoform average outside the 99 % confidence interval generated from all samples providing a simple measure of how much individual regions deviated from the average. Table S6. Genes with AEI. Lists the genes identified with potential allelic expression imbalance. Genes were required to have > 2 SNPs and an average coverage of 30 reads for those SNPs (IDCP 99 kb).

Additional file 2: Figure S1 Average expression of invariant genes in 4 GTEx brains. Shows the variation of 200 invariant genes expressed in 4 GTEx brain regions. (PDF 189 kb)

Additional file 3: Figure S2 Visualization of the results of differential expression analysis for four pairs of brain regions with highest differences in gene expression. Log fold-change (y-axis) and corresponding log–log FDR (x-axis) are shown for each gene. Genes differentially expressed (FDR < 0.05) are marked in red and top five DE genes for each pair are indicated. (TIF 915 kb)

Additional file 4: Figure S3 Pathway relating VEGF and other differentially expressed genes to smoking. Displays a pathway generated by Ingenuity Pathway Analysis using genes differentially expressed between smokers and nonsmokers in BA46 that connect to smoking and smoking related molecules. Differentially expressed genes are highlighted in green and smoking related molecules are outlined in purple. (PDF 80 kb)

Additional file 5: Figure S4 Plot of AEI ratio versus read depth across SNP. Displays the average magnitude of the allelic expression fold-change of a gene for a particular sample/region compared to the average read depth for SNPs in the gene. SNPs with low coverage tend to have more extreme AEI. (PDF 211 kb)

Additional file 6: Figure S5 Confirmation of expression levels by qRTPCR. qRTPCR was performed to correlate the FPKM of 3 invariably expressed genes between smokers and nonsmokers (FDR ≤ 0.05) are marked in red and top five DE genes for each pair are indicated. (y-axis) are shown for each gene. Genes differentially expressed (FDR < 0.05) are marked in red and top five DE genes for each pair are indicated. (PDF 206 kb)

Additional file 7: Figure S6 Comparison of NRXN3 isoform representation between OSU and GTEx brains. The ratio of the blue and orange isoforms favors ENST00000555383.1 in both GTEx and OSU in the cerebellum and favors ENST00000555387.1 in the other 3 overlapping regions. ENST00000555387.1 corresponds to NRXN3_dup5, and ENST00000555383.1 corresponds to NRXN3_dup3. The protein coding version ENST00000428277.2 is highly represented in GTEx brains likely due to poly-A selection. (PDF 173 kb)

Additional file 8: Figure S7 Comparison of NRXN3 isoform representation between OSU and GTEx brains. The ratio of the blue and orange isoforms favors ENST00000555383.1 in both GTEx and OSU in the cerebellum and favors ENST00000555387.1 in the other 3 overlapping regions. ENST00000555387.1 corresponds to NRXN3_dup5, and ENST00000555383.1 corresponds to NRXN3_dup3. The protein coding version ENST00000428277.2 is highly represented in GTEx brains likely due to poly-A selection. (PDF 173 kb)

Abbreviations
AEI: Allelic expression imbalance; BA: Broadmann area; CNS: Central nervous system; CPM: Counts per million; eQTL: Expression quantitative trait loci; FDR: False discovery rate; FPKM: Fragments Per Kilobase per Million reads; GO: Gene ontology; GTEx: Genotype-tissue expression project; GWAS: Genome-wide association study; IPA: Ingenuity pathway analysis; IUPAC: International Union of Pure and Applied Chemistry ambiguity codes for SNPs; lncRNA: Long intergenic noncoding RNA; ncRNA: Long noncoding RNA; ncRNA: Non-coding RNA; OMM: Online Mendelian inheritance in man; PCR: Polymerase chain reaction; RPKM: Reads Per Kilobase per Million reads; SNP: Single nucleotide polymorphism.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AW carried out bioinformatics data analysis and drafted manuscript. AP, AC, and LN prepared the samples and performed sequencing. MS, SH, and GR performed mathematical modeling. AW, MP, WS, AP, AC, DW, and EG participated in generating analysis plan and interpreting results. DM provided access to tissue samples. WS, AP, DM, CL, RT, JK conceived and designed the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This study is supported in part by the NIH National Institute of General Medical Sciences, Pharmacogenomics Research Network (PGRN) grant U01 GM092655 (WS), the RNA Sequencing Project (GMS1390), and grant #DA02627 (DCM).

Author details
1 Center for Pharmacogenomics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. 2 Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. 3 Division of Biostatistics, College of Public Health, and Mathematical Biosciences Institute, The Ohio State University, Columbus, OH, USA. 4 Thermo Fisher Scientific, South San Francisco, CA 94080, USA. 5 Center for Addiction and Mental Health and Departments of Psychiatry and Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada. 6 Department of Psychiatry, Annenberg School for Communication, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. 7 Department of Psychiatry, Laboratory of Psychiatric Genomics, University of California, San Diego, USA. 8 VA San Diego Healthcare System, La Jolla, San Diego, CA, USA. 9 Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA. 10 Departments of Pharmacology, College of Medicine; Colleges of Pharmacy and Environmental Health Sciences, The Ohio State University, Columbus, OH, USA. 11 Departments of Psychiatry, College of Medicine; Colleges of Pharmacy and Environmental Health Sciences, The Ohio State University, Columbus, OH, USA. 12 Departments of Human Genetics/Internal Medicine, College of Medicine; Colleges of Pharmacy and Environmental Health Sciences, The Ohio State University, Columbus, OH, USA.

Received: 20 February 2015 Accepted: 12 November 2015

Published online: 23 November 2015

References
1. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT, et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature. 2011;478(7370):519–23.
2. Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L, Szafir A, et al. Transcriptional landscape of the prenatal human brain. Nature. 2014;508(7495):199–206.
3. Ramasamy A, Trabzuni D, GueLL S, Varghese V, Smith C, Walker R, et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat Neurosci. 2014;17(10):1418–28.
4. Guennewig B, Cooper AA. The central role of noncoding RNA in the brain. Int Rev Neurobiol. 2014;116:153–94.
5. Sadee W, Hartmann K, Seweryn M, Pietrzak M, Handelman SK, Rempala GA. Missing heritability of common diseases and treatments outside the protein-coding exome. Hum Genet. 2014;133(1):1199–215.
6. Pandey AK, Williams RW. Genetics of gene expression in CNS. Int Rev Neurobiol. 2014;116:195–231.
7. Webb A, Papp AC, Sanford JC, Huang K, Parvin JD. Sadee W. Expression of mRNAs transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver. Pharmacogenet Genomics. 2013;23(5):269–78.
8. Solga AC, Pong WW, Walker J, Wylie T, Magrini V, Aparicieli AJ, et al. RNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease. Glia. 2014;63(4):531–48.
9. Li S, Tighe SW, Nicolet CM, Grove D, Levy S, Farrarere W, et al. Multi-platform assessment of transcriptional profiling using RNA-seq in the ABRF next-generation sequencing study. Nat Biotechnol. 2014;32(9):915–25.

10. Haghiri H, Ohtia K, Takao K, Miyakawa T. Transcriptomic evidence for immaturity of the prefrontal cortex in patients with schizophrenia. Mol Brain. 2014;7:41.

11. Zhang H, Wang F, Xu H, Liu Y, Liu J, Zhao H, et al. Differentially co-expressed genes in postmortem prefrontal cortex of individuals with alcohol use disorders: influence on alcohol metabolism-related pathways. Hum Genet. 2014;133(11):1383–94.

12. Zhou Z, Enoch MA, Goldman D. Gene expression in the addicted brain. Int Rev Neurobiol. 2014;116:251–73.

13. McCarthy MJ, Liang S, Spadoni AD, Kelsoe JR, Simmons AN. Whole brain expression of bipolar disorder associated genes: structural and genetic analyses. PLoS One. 2014;9(6):e100024.

14. Farris SP, Mayfield RD. RNA-Seq reveals novel transcriptional reorganization in human alcoholic brain. Int Rev Neurobiol. 2014;116:275–300.

15. Akula N, Barb J, Jiang X, Wendland KJ, Choi KH, Sen SK, et al. RNA-sequencing of the brain transcriptome implicates dysregulation of neuroplasticity, circadian rhythms and GTPase binding in bipolar disorder. Mol Psychiatry. 2014;19(11):1179–85.

16. Grange P, Bohlman JW, Okaty BW, Sugino K, Bolli H, Nelson SB, et al. Cell-type-based model explaining coexpression patterns of genes in the brain. Proc Natl Acad Sci U S A. 2014;111(14):5397–402.

17. Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL, et al. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010;6(5):e1000952.

18. Hernandez DG, Nalls MA, Moore M, Chong S, Dillman A, Trabzuni D, et al. Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for traits in blood and brain. Neurobiol Dis. 2012;47(1):20–8.

19. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, et al. Polyphenol expression in the hippocampus after chronic exposure to alcohol or cocaine. Genes Brain Behav. 2014;13(8):758–67.

20. Liu X, Liu M, Li X, Zhang L, Fan R, Wang J. Prioritizing genes related to nicotine addiction via a multi-source-based approach. Mol Neurobiol. 2015;52(1):442.

21. Azad AK, Sadee W, Schlesinger LS. Innate immune gene polymorphisms in African green monkeys. Neuropharmacology. 2013;72:74–83.

22. Smith RM, Alachkar H, Papp AC, Wang D, Mash DC, Wang JC, et al. Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal deaths. Am J Forensic Med Pathol. 2004;25(1):111–3.

23. Mash DC, Pablo J, Ouyang Q, Heim WL, Bienvenue S. Dopamine transport function is elevated in cocaine users. J Neurochem. 2002;82(2):292–300.

24. Harrow J, Frankish A, Gonzalez JM, Tapasani E, Diekhaus M, Kokocinski F, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012;22(9):1760–74.

25. Volders PJ, Helens K, Wang X, Menten B, Martens L, Gevaert K, et al. LNCipedia: a database for annotated human IncRNA transcript sequences and structures. Nucleic Acids Res. 2013;41(Database issue):D246–51.

26. Li S, Tighe SW, Levy S, Farrarere W, et al. Multiplatform assessment of transcriptional profiling using RNA-seq in the ABRF next-generation sequencing study. Nat Biotechnol. 2014;32(9):915–25.

27. Stephens BG, Jentzen JM, Karch S, Wett C, Mash DC. National Association of Medical Examiners position paper on the certification of cocaine-related deaths. Am J Forensic Med Pathol. 2004;25(1):111–3.

28. Mash DC, Pablo J, Ouyang Q, Heim WL, Bienvenue S. Dopamine transport function is elevated in cocaine users. J Neurochem. 2002;82(2):292–300.

29. Harrow J, Frankish A, Gonzalez JM, Tapasani E, Diekhaus M, Kokocinski F, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012;22(9):1760–74.

30. Volders PJ, Helens K, Wang X, Menten B, Martens L, Gevaert K, et al. LNCipedia: a database for annotated human IncRNA transcript sequences and structures. Nucleic Acids Res. 2013;41(Database issue):D246–51.

31. Condi DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, et al. Pharmacogenetics of Nicotine Addiction and Treatment Consortium: Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet. 2008;17(18):2834–48.

32. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923–30.

33. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(11):139–40.

34. Resso D, Ngl J, Speed T, Dudot S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol. 2014;32(9):896–902.

35. Chen J, Bardes EE, Aronov BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009;37(Web Server issue):W305–11.

36. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkulhi K, Thom CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–7.

37. Via A, Kucuk AK, Kizilhan D, Yetis E, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012;22(9):1760–74.

38. Volders PJ, Helens K, Wang X, Menten B, Martens L, Gevaert K, et al. LNCipedia: a database for annotated human IncRNA transcript sequences and structures. Nucleic Acids Res. 2013;41(Database issue):D246–51.

39. Genotype-Phenotype Integrator; PheGenI: synthesizing genome-wide association study: GWAS data with existing genomic resources. Eur J Hum Genet. 2014;22(11):1447–57.

40. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkulhi K, Thom CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–7.

41. Volders PJ, Helens K, Wang X, Menten B, Martens L, Gevaert K, et al. LNCipedia: a database for annotated human IncRNA transcript sequences and structures. Nucleic Acids Res. 2013;41(Database issue):D246–51.

42. Chen J, Bardes EE, Aronov BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009;37(Web Server issue):W305–11.

43. Li H, Handaker B, Wysoke J, Fennell T, Ruan J, Horner N, et al. 1000 Genome Project Data Processing Subgroup: The Sequence Alignment/Map format and SAtools. Bioinformatics. 2009;25(16):2078–9.

44. Michaud SE, Dussault S, Golueke J, Huerta A, Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers. Br J Biomed Sci. 2000;57(3):207–9.

45. Burnell-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkulhi K, Thom CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–7.

46. Petryszak R, Burdett T, Fiorelli B, Fonseca NA, Gonzalez-Porta M, Hastings E, et al. Expression Atlas update—a database of gene and transcript expression from microarray- and sequencing-based functional genomics experiments. Nucleic Acids Res. 2014;42(Database issue):D926–32.

47. Seshadri S, DeStefano AL, Au R, Massaro JM, Beiser AS, Kelly-Hayes M, et al. Genetic correlates of brain aging on MRI and cognitive test measures: a update. Alcohol Res Health. 2002;26(3):214–6.

48. Belgore FM, Lip CQ, Baron AD. Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers. Br J Biomed Sci. 2000;57(3):207–9.

49. Belgore FM, Lip CQ, Baron AD. Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers. Br J Biomed Sci. 2000;57(3):207–9.

50. Schmidt-Lucke C, Belgore F, Reinhold D, Ansorge S, Klein HU, Schmidt-Lucke C, et al. Ethanol self-administration in the rat impairs regional cerebral blood flow: a functional magnetic resonance imaging study. Neuroimage. 2010;50(4):1191–9.